HNK20 monoclonal IgA antibody: Began Phase I trial

OraVax Inc., Cambridge, Mass. Product: HNK20 monoclonal IgA antibody to be delivered intranasally Indication: Prevent and treat respiratory syncytial virus Status: Began Phase I trial in 19 healthy ad...